Managing Weight and Metabolic Outcomes in PCOS with BMI ≥ 25 kg/m²

Women with polycystic ovarian syndrome (PCOS) who have a BMI of 25 kg/m² or above face compounded metabolic risk. In this sub-population, addressing weight is integral to the broader management of the condition.

This protocol applies to adults with PCOS and BMI ≥ 25 kg/m² in whom both weight reduction and improvement of metabolic outcomes are clinical priorities.

Approach

Management in this setting combines lifestyle intervention with adjunctive pharmacological support targeting obesity — the full structured regimen, including the specific agents and sequencing recommended for this population, is outlined in the complete protocol. Further detail is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

Anti-obesity medications in addition to lifestyle, could be considered for the management of obesity in adults with PCOS after lifestyle intervention, as per general population recommendations.

Metformin in addition to lifestyle, should be considered in adult women with PCOS with BMI ≥ 25 kg/m² for management of weight and metabolic outcomes.

DOI: 10.1016/j.fertnstert.2023.07.025

View source ↗